The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

CRISPR/Cas9 technology was used to abrogate p210 oncoprotein expression in the Boff-p210 cell line, a pro-B line derived from interlukin-3-dependent Baf/3, that shows IL-3-independence arising from the constitutive expression of BCR-ABL p210. Using this approach, pools of Boff-p210-edited cells and...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Tuñón, Ignacio, Hernández-Sánchez, María, Ordoñez, José Luis, Alonso-Pérez, Veronica, Álamo-Quijada, Miguel, Benito, Rocio, Guerrero, Carmen, Hernández-Rivas, Jesús María, Sánchez-Martín, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432235/
https://www.ncbi.nlm.nih.gov/pubmed/28212528
http://dx.doi.org/10.18632/oncotarget.15215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432235/
https://www.ncbi.nlm.nih.gov/pubmed/28212528
http://dx.doi.org/10.18632/oncotarget.15215

Ejemplares similares